National Health (Floor Price for Certain Brands of Pharmaceutical Items) Determination 2023

1 Name

(1) This instrument is the National Health (Floor Price for Certain Brands of Pharmaceutical Items) Determination 2023.

(2) This instrument may also be cited as PB 10 of 2023.

3 Authority

This instrument is made under subsection 99ADHC(2) of the National Health Act 1953.

4 Definitions

In this instrument:

Act means the National Health Act 1953.

brand has the same meaning as in Part VII of the Act.

pharmaceutical item has the same meaning as in Part VII of the Act.

5 Floor price of certain brands of pharmaceutical items

For the purposes of subsection 99ADHC(2) of the Act, paragraph 99ADHC(1)(c) of the Act applies to a brand mentioned in column 1 of an item in the following table of a pharmaceutical item that is the drug mentioned in column 2 of that table item, in the form mentioned in column 3 of that table item and with the manner of administration mentioned in column 4 of that table item.

Floor price of certain brands of pharmaceutical items
Column 1 Brand	Column 2 Drug	Column 3 Form	Column 4 Manner of administration
PKU squeezie	Amino acid formula with vitamins and minerals without phenylalanine	Oral gel 85 g, 30 (PKU squeezie)	Oral
Kineret	Anakinra	Injection 100 mg in 0.67 mL single use pre‑filled syringe	Injection
Bicillin L‑A	Benzathine benzylpenicillin	Injection containing 1,200,000 units benzathine benzylpenicillin tetrahydrate in 2.3 mL single use pre‑filled syringe	Injection
Bicillin L‑A	Benzathine benzylpenicillin	Injection containing 600,000 units benzathine benzylpenicillin tetrahydrate in 1.17 mL single use pre‑filled syringe	Injection
Cal‑500	Calcium	Tablet, chewable, 500 mg (as carbonate)	Oral
Largactil	Chlorpromazine	Injection containing chlorpromazine hydrochloride 50 mg in 2 mL	Injection
Largactil	Chlorpromazine	Oral solution containing chlorpromazine hydrochloride 25 mg per 5 mL, 100 mL	Oral
Largactil	Chlorpromazine	Tablet containing chlorpromazine hydrochloride 100 mg	Oral
Largactil	Chlorpromazine	Tablet containing chlorpromazine hydrochloride 25 mg	Oral
Dantrium	Dantrolene	Capsule containing dantrolene sodium hemiheptahydrate 25 mg	Oral
DBL Desferrioxamine Mesilate	Desferrioxamine	Powder for injection containing desferrioxamine mesilate 2 g	Injection
Cardizem	Diltiazem	Tablet containing diltiazem hydrochloride 60 mg	Oral
Diltiazem AN	Diltiazem	Tablet containing diltiazem hydrochloride 60 mg	Oral
Vasocardol	Diltiazem	Tablet containing diltiazem hydrochloride 60 mg	Oral
ADT Booster	Diphtheria and tetanus vaccine, adsorbed, diluted for adult use	Injection 0.5 mL in pre‑filled syringe	Injection
Triumeq	Dolutegravir with abacavir and lamivudine	Tablet containing dolutegravir 50 mg with abacavir 600 mg and lamivudine 300 mg	Oral
Estraderm MX 50	Estradiol	Transdermal patches 1.5 mg (as hemihydrate), 8	Transdermal
Estraderm MX 100	Estradiol	Transdermal patches 3 mg (as hemihydrate), 8	Transdermal
Estraderm MX 25	Estradiol	Transdermal patches 750 micrograms (as hemihydrate), 8	Transdermal
Flucil	Flucloxacillin	Powder for injection 1 g (as sodium monohydrate)	Injection
Flucil	Flucloxacillin	Powder for oral liquid 125 mg (as sodium monohydrate) per 5 mL, 100 mL	Oral
Flucil	Flucloxacillin	Powder for oral liquid 250 mg (as sodium monohydrate) per 5 mL, 100 mL	Oral
DBL Heparin Sodium	Heparin	Injection 5,000 units (as sodium) in 0.2 ml	Injection
Moduretic	Hydrochlorothiazide with amiloride	Tablet containing hydrochlorothiazide 50 mg with amiloride hydrochloride 5 mg	Oral
Hymenoptera Honey Bee Venom	Insect allergen extract‑honey bee venom	Injection set containing 550 micrograms with diluent	Injection
Hymenoptera Paper Wasp Venom	Insect allergen extract‑paper wasp venom	Injection set containing 550 micrograms with diluent	Injection
Hymenoptera Yellow Jacket Venom	Insect allergen extract‑yellow jacket venom	Injection set containing 550 micrograms with diluent	Injection
Toujeo Solostar	Insulin glargine	Injections (human analogue), cartridge, 300 units per mL, 1.5 mL, 3	Injection
Toujeo Solostar	Insulin glargine	Injections (human analogue), cartridges, 300 units per mL, 1.5 mL, 5	Injection
Lithicarb	Lithium	Tablet containing lithium carbonate 250 mg	Oral
Quilonum SR	Lithium	Tablet containing lithium carbonate 450 mg (slow release)	Oral
OsmoLax	Macrogol 3350	Powder for oral solution 510 g	Oral
Penthrox	Methoxyflurane	Liquid for inhalation 999 mg per g, 3 ml (with inhaler)	Inhalation by mouth
Flagyl	Metronidazole	Suppositories 500 mg, 10	Rectal
Carbohydrate Free Mixture	Milk protein and fat formula with vitamins and minerals ‑‑ carbohydrate free	Oral powder 225 g (Carbohydrate Free Mixture)	Oral
MORPHINE SULFATE 15 mg/1 mL MEDSURGE	Morphine	Injection containing morphine sulfate pentahydrate 15 mg in 1 mL	Injection
MORPHINE SULFATE 30 mg/1 mL MEDSURGE	Morphine	Injection containing morphine sulfate pentahydrate 30 mg in 1 mL	Injection
Ditropan	Oxybutynin	Tablet containing oxybutynin hydrochloride 5 mg	Oral
Oxytrol	Oxybutynin	Transdermal patches 36 mg, 8	Transdermal
Neulactil	Periciazine	Tablet 10 mg	Oral
Neulactil	Periciazine	Tablet 2.5 mg	Oral
Lyclear	Permethrin	Cream 50 mg per g, 30 g	Application
Elidel	Pimecrolimus	Cream 10 mg per g, 15 g	Application
Pro‑Cid	Probenecid	Tablet 500 mg	Oral
Stemetil	Prochlorperazine	Injection containing prochlorperazine mesilate 12.5 mg in 1 mL	Injection
Aptamil Gold+ Pepti‑Junior	Protein hydrolysate formula with medium chain triglycerides	Oral powder 450 g (Aptamil Gold+ Pepti‑Junior)	Oral
Asmol CFC‑Free with dose counter	Salbutamol	Pressurised inhalation 100 micrograms (as sulfate) per dose with dose counter, 200 doses (CFC‑free formulation)	Inhalation by mouth
Ventolin CFC‑Free with dose counter	Salbutamol	Pressurised inhalation 100 micrograms (as sulfate) per dose with dose counter, 200 doses (CFC‑free formulation)	Inhalation by mouth
Zempreon CFC‑Free with dose counter	Salbutamol	Pressurised inhalation 100 micrograms (as sulfate) per dose with dose counter, 200 doses (CFC‑free formulation)	Inhalation by mouth
Eldepryl	Selegiline	Tablet containing selegiline hydrochloride 5 mg	Oral
PHOSPHATE PHEBRA	Sodium acid phosphate	Tablet, compound effervescent, equivalent to 500 mg phosphorus	Oral
Micolette	Sorbitol with sodium citrate dihydrate and sodium lauryl sulfoacetate	Enemas 3.125 g‑450 mg‑45 mg in 5 mL, 12	Rectal
Lipistart	Triglycerides ‑ medium chain, formula	Oral powder 400 g (Lipistart)	Oral
K.Quik	Triglycerides, medium chain	Oral liquid 225 mL, 15 (K.Quik)	Oral
Epilim Liquid	Valproic acid	Oral liquid containing sodium valproate 200 mg per 5 mL, 300 mL	Oral
Epilim Syrup	Valproic acid	Oral solution containing sodium valproate 200 mg per 5 mL, 300 mL	Oral

Endnotes

Endnote 1—About the endnotes

The endnotes provide information about this compilation and the compiled law.

The following endnotes are included in every compilation:

Endnote 1—About the endnotes

Endnote 2—Abbreviation key

Endnote 3—Legislation history

Endnote 4—Amendment history

Abbreviation key—Endnote 2

The abbreviation key sets out abbreviations that may be used in the endnotes.

Legislation history and amendment history—Endnotes 3 and 4

Amending laws are annotated in the legislation history and amendment history.

The legislation history in endnote 3 provides information about each law that has amended (or will amend) the compiled law. The information includes commencement details for amending laws and details of any application, saving or transitional provisions that are not included in this compilation.

The amendment history in endnote 4 provides information about amendments at the provision (generally section or equivalent) level. It also includes information about any provision of the compiled law that has been repealed in accordance with a provision of the law.

Editorial changes

The Legislation Act 2003 authorises First Parliamentary Counsel to make editorial and presentational changes to a compiled law in preparing a compilation of the law for registration. The changes must not change the effect of the law. Editorial changes take effect from the compilation registration date.

If the compilation includes editorial changes, the endnotes include a brief outline of the changes in general terms. Full details of any changes can be obtained from the Office of Parliamentary Counsel.

Misdescribed amendments

A misdescribed amendment is an amendment that does not accurately describe how an amendment is to be made. If, despite the misdescription, the amendment can be given effect as intended, then the misdescribed amendment can be incorporated through an editorial change made under section 15V of the Legislation Act 2003.

If a misdescribed amendment cannot be given effect as intended, the amendment is not incorporated and “(md not incorp)” is added to the amendment history.

Endnote 2—Abbreviation key

ad = added or inserted	o = order(s)
am = amended	Ord = Ordinance
amdt = amendment	orig = original
c = clause(s)	par = paragraph(s)/subparagraph(s)
C[x] = Compilation No. x	/sub‑subparagraph(s)
Ch = Chapter(s)	pres = present
def = definition(s)	prev = previous
Dict = Dictionary	(prev…) = previously
disallowed = disallowed by Parliament	Pt = Part(s)
Div = Division(s)	r = regulation(s)/rule(s)
ed = editorial change	reloc = relocated
exp = expires/expired or ceases/ceased to have	renum = renumbered
effect	rep = repealed
F = Federal Register of Legislation	rs = repealed and substituted
gaz = gazette	s = section(s)/subsection(s)
LA = Legislation Act 2003	Sch = Schedule(s)
LIA = Legislative Instruments Act 2003	Sdiv = Subdivision(s)
(md) = misdescribed amendment can be given	SLI = Select Legislative Instrument
effect	SR = Statutory Rules
(md not incorp) = misdescribed amendment	Sub‑Ch = Sub‑Chapter(s)
cannot be given effect	SubPt = Subpart(s)
mod = modified/modification	underlining = whole or part not
No. = Number(s)	commenced or to be commenced

Endnote 3—Legislation history

Name	Registration	Commencement	Application, saving and transitional provisions
National Health (Floor Price for Certain Brands of Pharmaceutical Items) Determination 2023 (PB 10 of 2023)	31 May 2023 (F2023N00143)	1 June 2023 (s 2(1) item 1)
National Health (Floor Price for Certain Brands of Pharmaceutical Items) Amendment Determination (No. 1) 2023 (PB 104 of 2023)	5 Oct 2023 (F2023N00372)	Sch 1: 6 Oct 2023 (s 2(1) item 2) Sch 2: 1 Apr 2024 (s 2(1) item 3)	—
National Health (Floor Price for Certain Brands of Pharmaceutical Items) Amendment Determination (No. 1) 2024 (PB 11 of 2024)	7 Feb 2024 (F2024N00127)	Sch 1: 1 June 2024 (s 2(1) item 2)	—
National Health (Floor Price for Certain Brands of Pharmaceutical Items) Amendment Determination (No. 2) 2024 (PB 33 of 2024)	29 Apr 2024 (F2024N00358)	Sch 1: 1 Aug 2024 (s 2(1) item 2) Sch 2: 1 Oct 2024 (s 2(1) item 3)	—

Endnote 4—Amendment history

Provision affected	How affected
s 2.....................	rep LA s 48D
s 5.....................	rs F2023N00372
	am F2023N00372; F2024N00127; F2024N00358